Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone in Bipolar Disorder With Comorbid Panic or Generalized Anxiety Disorder
NCT01172652Phase 4Completed
- Sponsor
- VA Palo Alto Health Care System
- Start
- Apr 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in bipolar disorder (BD), panic disorder and generalized anxiety disorder (GAD) comparing Ziprasidone with Placebo (2 arms). Primary endpoint: Clinician Global Improvement Scale at 8 weeks. Started Apr 2010; status: completed.
02
Drugs
ziprasidone
03
Conditions
bipolar disorder (BD)panic disordergeneralized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT01172652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172652.